A gynecological preparation from Richter has received marketing authorization in Japan
The partner of Richter Gedeon Nyrt., Fuji Pharma Co., Ltd., received the marketing authorization for the Alyssa combination tablet developed in Japan. The approval means a milestone payment of 10 million euros for Richter’s 100 percent subsidiary, Estetra SRL, Richter announced on Tuesday on the website of the Budapest Stock Exchange.
The Alyssa combined tablet is a preparation for the treatment of dysmenorrhea – painful, crampy menstruation – which contains, among other things, a natural estrogen (estetrol), which has marketing rights in Japan and Southeast Asia.
In the Association of Nations (ASEAN) region, Fuji acquired it from Estetra SRL.
Fuji Alyssa is preparing to launch the combination pill under the trade name to provide a new treatment option for dysmenorrhoea patients.
Related news
Richter CEO: performance is in line with annual plans
At Richter Gedeon Plc., the first half-year performance was in…
Read more >Richter CEO: the company achieved good performance in the first quarter
Richter achieved a good performance in the first quarter and…
Read more >Young people value sustainability and environmental protection the most
According to the a joint survey by the Bosch Group…
Read more >Related news
OKSZ: Retail is not responsible for rising prices
The 3 percent annual increase in retail sales in June,…
Read more >Hungarian startup measures carbon footprint of largest domestic webshops
Carbon.Crane, the first Hungarian startup dedicated to ISO-compatible digital carbon…
Read more >The role of Hungarian product trademarks has further strengthened
In the case of food, 86.6 percent of buyers prefer…
Read more >